The inhibition of the renin-angiotensin-aldosterone system (RAAS) is a essential aspect of the medical treatment of several chronic cardiovascular, metabolic, and renal conditions. It plays a vital role in managing chronic heart failure (CHF), particularly CHF with reduced ejection fraction, and also in chronic kidney disease (CKD), diabetes mellitus (DM), ischemic heart disease (IHD), and hypertension (HTN). Extensive evidence from randomized clinical trials supports the benefits of RAAS inhibition (RAASI) in these patient populations, demonstrating improvements in important clinical outcomes, including mortality and hospitalizations.
